Search

Your search keyword '"MacCamy, Anna J."' showing total 14 results
Start Over Author "MacCamy, Anna J."
14 results on '"MacCamy, Anna J."'

2. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

Author

Gray, Matthew D., primary, Feng, Junli, additional, Weidle, Connor E., additional, Cohen, Kristen W., additional, Ballweber-Fleming, Lamar, additional, MacCamy, Anna J., additional, Huynh, Crystal N., additional, Trichka, Josephine J., additional, Montefiori, David, additional, Ferrari, Guido, additional, Pancera, Marie, additional, McElrath, M. Juliana, additional, and Stamatatos, Leonidas, additional

Published
2022
Full Text
View/download PDF

3. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

Author

Gray, Matthew D., primary, Feng, Junli, additional, Weidle, Connor E., additional, Cohen, Kristen W., additional, Ballweber-Fleming, Lamar, additional, MacCamy, Anna J., additional, Huynh, Crystal N., additional, Trichka, Josephine J., additional, Montefiori, David, additional, Ferrari, Guido, additional, Pancera, Marie, additional, McElrath, M. Juliana, additional, and Stamatatos, Leonidas, additional

Published
2021
Full Text
View/download PDF

4. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

Author

Hurlburt, Nicholas K., primary, Homad, Leah J., additional, Sinha, Irika, additional, Jennewein, Madeleine F., additional, MacCamy, Anna J., additional, Wan, Yu-Hsin, additional, Boonyaratanakornkit, Jim, additional, Sholukh, Anton M., additional, Zhou, Panpan, additional, Burton, Dennis R., additional, Andrabi, Raiees, additional, Stamatatos, Leonidas, additional, Pancera, Marie, additional, and McGuire, Andrew T., additional

Published
2021
Full Text
View/download PDF

5. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

Author

Jennewein, Madeleine F., primary, MacCamy, Anna J., additional, Akins, Nicholas R., additional, Feng, Junli, additional, Homad, Leah J., additional, Hurlburt, Nicholas K., additional, Seydoux, Emilie, additional, Wan, Yu-Hsin, additional, Stuart, Andrew B., additional, Edara, Venkata Viswanadh, additional, Floyd, Katharine, additional, Vanderheiden, Abigail, additional, Mascola, John R., additional, Doria-Rose, Nicole, additional, Wang, Lingshu, additional, Yang, Eun Sung, additional, Chu, Helen Y., additional, Torres, Jonathan L., additional, Ozorowski, Gabriel, additional, Ward, Andrew B., additional, Whaley, Rachael E., additional, Cohen, Kristen W., additional, Pancera, Marie, additional, McElrath, M. Juliana, additional, Englund, Janet A., additional, Finzi, Andrés, additional, Suthar, Mehul S., additional, McGuire, Andrew T., additional, and Stamatatos, Leonidas, additional

Published
2021
Full Text
View/download PDF

6. Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies

Author

Seydoux, Emilie, primary, Wan, Yu-Hsin, additional, Feng, Junli, additional, Wall, Abigail, additional, Aljedani, Safia, additional, Homad, Leah J., additional, MacCamy, Anna J., additional, Weidle, Connor, additional, Gray, Matthew D., additional, Brumage, Lauren, additional, Taylor, Justin J., additional, Pancera, Marie, additional, Stamatatos, Leonidas, additional, and McGuire, Andrew T., additional

Published
2021
Full Text
View/download PDF

7. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Author

Stamatatos, Leonidas, primary, Czartoski, Julie, additional, Wan, Yu-Hsin, additional, Homad, Leah J., additional, Rubin, Vanessa, additional, Glantz, Hayley, additional, Neradilek, Moni, additional, Seydoux, Emilie, additional, Jennewein, Madeleine F., additional, MacCamy, Anna J., additional, Feng, Junli, additional, Mize, Gregory, additional, De Rosa, Stephen C., additional, Finzi, Andrés, additional, Lemos, Maria P., additional, Cohen, Kristen W., additional, Moodie, Zoe, additional, McElrath, M. Juliana, additional, and McGuire, Andrew T., additional

Published
2021
Full Text
View/download PDF

8. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Author

Stamatatos, Leonidas, primary, Czartoski, Julie, additional, Wan, Yu-Hsin, additional, Homad, Leah J., additional, Rubin, Vanessa, additional, Glantz, Hayley, additional, Neradilek, Moni, additional, Seydoux, Emilie, additional, Jennewein, Madeleine F., additional, MacCamy, Anna J., additional, Feng, Junli, additional, Mize, Gregory, additional, De Rosa, Stephen C., additional, Finzi, Andrés, additional, Lemos, Maria P., additional, Cohen, Kristen W., additional, Moodie, Zoe, additional, McElrath, M. Juliana, additional, and McGuire, Andrew T., additional

Published
2021
Full Text
View/download PDF

9. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Author

Seydoux, Emilie, primary, Homad, Leah J., additional, MacCamy, Anna J., additional, Parks, K. Rachael, additional, Hurlburt, Nicholas K., additional, Jennewein, Madeleine F., additional, Akins, Nicholas R., additional, Stuart, Andrew B., additional, Wan, Yu-Hsin, additional, Feng, Junli, additional, Whaley, Rachael E., additional, Singh, Suruchi, additional, Boeckh, Michael, additional, Cohen, Kristen W., additional, McElrath, M. Juliana, additional, Englund, Janet A., additional, Chu, Helen Y., additional, Pancera, Marie, additional, McGuire, Andrew T., additional, and Stamatatos, Leonidas, additional

Published
2020
Full Text
View/download PDF

10. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

Author

Seydoux, Emilie, primary, Homad, Leah J., additional, MacCamy, Anna J., additional, Parks, K. Rachael, additional, Hurlburt, Nicholas K., additional, Jennewein, Madeleine F., additional, Akins, Nicholas R., additional, Stuart, Andrew B., additional, Wan, Yu-Hsin, additional, Feng, Junli, additional, Nelson, Rachael E., additional, Singh, Suruchi, additional, Cohen, Kristen W., additional, McElrath, M. Juliana, additional, Englund, Janet A., additional, Chu, Helen Y., additional, Pancera, Marie, additional, McGuire, Andrew T., additional, and Stamatatos, Leonidas, additional

Published
2020
Full Text
View/download PDF

11. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization

Author

Parks, K. Rachael, primary, MacCamy, Anna J., additional, Trichka, Josephine, additional, Gray, Matthew, additional, Weidle, Connor, additional, Borst, Andrew J., additional, Khechaduri, Arineh, additional, Takushi, Brittany, additional, Agrawal, Parul, additional, Guenaga, Javier, additional, Wyatt, Richard T., additional, Coler, Rhea, additional, Seaman, Michael, additional, LaBranche, Celia, additional, Montefiori, David C., additional, Veesler, David, additional, Pancera, Marie, additional, McGuire, Andrew, additional, and Stamatatos, Leonidas, additional

Published
2019
Full Text
View/download PDF

12. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects.

Author

Jennewein MF, MacCamy AJ, Akins NR, Feng J, Homad LJ, Hurlburt NK, Seydoux E, Wan YH, Stuart AB, Edara VV, Floyd K, Vanderheiden A, Mascola JR, Doria-Rose N, Wang L, Yang ES, Chu HY, Torres JL, Ozorowski G, Ward AB, Whaley RE, Cohen KW, Pancera M, McElrath MJ, Englund JA, Finzi A, Suthar MS, McGuire AT, and Stamatatos L

Abstract

SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterized 198 antibodies isolated from four COVID19+ subjects and identified 14 SARS-CoV-2 neutralizing antibodies. One targeted the NTD, one recognized an epitope in S2 and twelve bound the RBD. Three anti-RBD neutralizing antibodies cross-neutralized SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency rather than the antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. The anti-S2 antibody also neutralized SARS-CoV-1 and all four cross-neutralizing antibodies neutralized the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.

Published
2021
Full Text
View/download PDF

13. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.

Author

Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos MP, Cohen KW, Moodie Z, McElrath MJ, and McGuire AT

Abstract

Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.

Published
2021
Full Text
View/download PDF

14. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.

Author

Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Nelson RE, Singh S, Cohen KW, McElrath MJ, Englund JA, Chu HY, Pancera M, McGuire AT, and Stamatatos L

Abstract

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one days post-infection. Forty-four S2P-specific monoclonal antibodies were generated, three of which bound to the receptor binding domain (RBD). The antibodies were minimally mutated from germline and were derived from different B cell lineages. Only two antibodies displayed neutralizing activity against SARS-CoV-2 pseudo-virus. The most potent antibody bound the RBD in a manner that prevented binding to the ACE2 receptor, while the other bound outside the RBD. Our study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 spike-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive/therapeutic potential and can serve as templates for vaccine-design., Competing Interests: DECLARATION OF INTERESTS The authors declare no competing financial interests. A provisional patent application on the antibodies discussed here has been filed. HYC: Merck, Sanofi-Pasteur, GSK

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results